A Randomized, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection.

Trial Profile

A Randomized, Placebo-Controlled Phase II Study of Multiple Dosing Regimens of Intravaginally Administered 851B Gel for the Treatment of Cervical High Risk HPV Infection.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Epetirimod (Primary)
  • Indications Cervical dysplasia; Human papillomavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Sep 2008 Actual patient number (538) added as reported by ClinicalTrials.gov.
    • 10 Sep 2008 Planned end date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 10 Sep 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top